MX2018001350A - Procesos para preparar un inhibidor de fgfr. - Google Patents

Procesos para preparar un inhibidor de fgfr.

Info

Publication number
MX2018001350A
MX2018001350A MX2018001350A MX2018001350A MX2018001350A MX 2018001350 A MX2018001350 A MX 2018001350A MX 2018001350 A MX2018001350 A MX 2018001350A MX 2018001350 A MX2018001350 A MX 2018001350A MX 2018001350 A MX2018001350 A MX 2018001350A
Authority
MX
Mexico
Prior art keywords
preparing
processes
fgfr inhibitor
fgfr
inhibitor
Prior art date
Application number
MX2018001350A
Other languages
English (en)
Inventor
Zhu Jiang
Masjedizadeh Mohammad
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2018001350A publication Critical patent/MX2018001350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02—Reduction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/06—Decomposition, e.g. elimination of halogens, water or hydrogen halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B39/00—Halogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B45/00—Formation or introduction of functional groups containing sulfur
    • C07B45/04—Formation or introduction of functional groups containing sulfur of sulfonyl or sulfinyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En este documento se divulgan procesos para preparar 8-(3-(4-acriloilpiperazin-1-il)propil)-6-(2,6-dicloro-3,5-dimetox ifenil)-2-(metilamino)pirido[2,3-d]pirimidin-7(8H)-onae inhibidor de FGFR, así como polimorfos y/o formas salinas de la misma.
MX2018001350A 2015-08-11 2016-08-10 Procesos para preparar un inhibidor de fgfr. MX2018001350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203498P 2015-08-11 2015-08-11
PCT/US2016/046304 WO2017027567A1 (en) 2015-08-11 2016-08-10 Processes for preparing an fgfr inhibitor

Publications (1)

Publication Number Publication Date
MX2018001350A true MX2018001350A (es) 2018-05-22

Family

ID=56694273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001350A MX2018001350A (es) 2015-08-11 2016-08-10 Procesos para preparar un inhibidor de fgfr.

Country Status (10)

Country Link
US (3) US10538518B2 (es)
EP (1) EP3334735A1 (es)
JP (1) JP6940480B2 (es)
KR (1) KR102183356B1 (es)
CN (1) CN107922410A (es)
AU (2) AU2016304852B2 (es)
CA (1) CA2993356C (es)
HK (1) HK1257197A1 (es)
MX (1) MX2018001350A (es)
WO (1) WO2017027567A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7226804B2 (ja) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド Ｆｇｆｒキナーゼ阻害剤及び医薬用途
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
DK1685131T3 (da) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
WO2008150260A1 (en) 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
IT1395724B1 (it) 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
RU2015137596A (ru) * 2013-03-14 2017-04-17 Пфайзер Инк. Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого
WO2014182829A1 (en) * 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
WO2015120049A1 (en) 2014-02-07 2015-08-13 Principia Biopharma, Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors

Also Published As

Publication number Publication date
AU2016304852A1 (en) 2018-02-15
HK1257197A1 (zh) 2019-10-18
AU2016304852B2 (en) 2020-12-10
CN107922410A (zh) 2018-04-17
US20180215756A1 (en) 2018-08-02
CA2993356C (en) 2021-01-19
US20210147417A1 (en) 2021-05-20
CA2993356A1 (en) 2017-02-16
AU2021201177B2 (en) 2022-12-22
KR20180033514A (ko) 2018-04-03
US20200148680A1 (en) 2020-05-14
JP6940480B2 (ja) 2021-09-29
US10538518B2 (en) 2020-01-21
WO2017027567A1 (en) 2017-02-16
JP2018522928A (ja) 2018-08-16
AU2021201177A1 (en) 2021-03-11
KR102183356B1 (ko) 2020-11-27
EP3334735A1 (en) 2018-06-20
US10899760B2 (en) 2021-01-26

Similar Documents

Publication Publication Date Title
IL267458A (en) Imidazolo[c-4,5]pyridine derivatives as stimulators of 1pd-l internalization
HK1258857A1 (zh) 作為lrrk2抑制劑的新穎咪唑並[4，5-c]喹啉和咪唑並[4，5- c][1，5]萘啶衍生物
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
IL261231B (en) Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors
HK1244787A1 (zh) 作為吲哚胺2，3-二加氧酶和/或色氨酸2，3-二加氧酶抑制劑的新穎的5或8-取代的咪唑並[1，5-a]吡啶
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
PL3345907T3 (pl) Związki pirazolo[3,4-d]pirymidynowe lub ich sole
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
GB201502260D0 (en) Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
MX2018001350A (es) Procesos para preparar un inhibidor de fgfr.
HUE047822T2 (hu) Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok
HK1257427A1 (zh) 用於製備2-吡唑並[1，5-a]吡嗪-2-基吡啶並[1，2-a]嘧啶-4-酮的方法
HUE050298T2 (hu) Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói
TH1601003657A (th) อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส